PMC:7306567 / 16239-17641 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T20","span":{"begin":844,"end":850},"obj":"Body_part"},{"id":"T21","span":{"begin":1256,"end":1262},"obj":"Body_part"}],"attributes":[{"id":"A20","pred":"fma_id","subj":"T20","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-PubTator

{"project":"LitCovid-PubTator","denotations":[{"id":"181","span":{"begin":98,"end":110},"obj":"Chemical"},{"id":"182","span":{"begin":115,"end":128},"obj":"Chemical"},{"id":"183","span":{"begin":161,"end":174},"obj":"Chemical"},{"id":"184","span":{"begin":205,"end":211},"obj":"Chemical"},{"id":"185","span":{"begin":227,"end":241},"obj":"Chemical"},{"id":"186","span":{"begin":243,"end":248},"obj":"Chemical"},{"id":"187","span":{"begin":280,"end":285},"obj":"Chemical"},{"id":"188","span":{"begin":338,"end":343},"obj":"Chemical"},{"id":"189","span":{"begin":520,"end":525},"obj":"Chemical"},{"id":"190","span":{"begin":599,"end":605},"obj":"Chemical"},{"id":"191","span":{"begin":752,"end":764},"obj":"Chemical"},{"id":"192","span":{"begin":858,"end":870},"obj":"Chemical"},{"id":"193","span":{"begin":1215,"end":1228},"obj":"Chemical"},{"id":"194","span":{"begin":827,"end":835},"obj":"Disease"},{"id":"195","span":{"begin":1066,"end":1081},"obj":"Disease"}],"attributes":[{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"MESH:D065819"},{"id":"A182","pred":"tao:has_database_id","subj":"182","obj":"MESH:C508735"},{"id":"A183","pred":"tao:has_database_id","subj":"183","obj":"MESH:D054714"},{"id":"A184","pred":"tao:has_database_id","subj":"184","obj":"MESH:D001393"},{"id":"A185","pred":"tao:has_database_id","subj":"185","obj":"MESH:D000666"},{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"MESH:C068538"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:D001393"},{"id":"A188","pred":"tao:has_database_id","subj":"188","obj":"MESH:C068538"},{"id":"A189","pred":"tao:has_database_id","subj":"189","obj":"MESH:C068538"},{"id":"A190","pred":"tao:has_database_id","subj":"190","obj":"MESH:D001393"},{"id":"A191","pred":"tao:has_database_id","subj":"191","obj":"MESH:D065819"},{"id":"A192","pred":"tao:has_database_id","subj":"192","obj":"MESH:D065819"},{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:C508735"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"MESH:D064420"},{"id":"A195","pred":"tao:has_database_id","subj":"195","obj":"MESH:C536203"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":969,"end":971},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T102","span":{"begin":130,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T103","span":{"begin":240,"end":241},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T104","span":{"begin":243,"end":248},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9940"},{"id":"T105","span":{"begin":296,"end":297},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T106","span":{"begin":338,"end":343},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9940"},{"id":"T107","span":{"begin":520,"end":525},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9940"},{"id":"T108","span":{"begin":695,"end":697},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T109","span":{"begin":771,"end":772},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T110","span":{"begin":844,"end":850},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T111","span":{"begin":977,"end":978},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T112","span":{"begin":1206,"end":1208},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T113","span":{"begin":1256,"end":1262},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T114","span":{"begin":1348,"end":1349},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-PD-CHEBI

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T28","span":{"begin":86,"end":89},"obj":"Phenotype"}],"attributes":[{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0020103"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T108","span":{"begin":0,"end":52},"obj":"Sentence"},{"id":"T109","span":{"begin":53,"end":138},"obj":"Sentence"},{"id":"T110","span":{"begin":139,"end":381},"obj":"Sentence"},{"id":"T111","span":{"begin":382,"end":512},"obj":"Sentence"},{"id":"T112","span":{"begin":513,"end":699},"obj":"Sentence"},{"id":"T113","span":{"begin":700,"end":836},"obj":"Sentence"},{"id":"T114","span":{"begin":837,"end":1082},"obj":"Sentence"},{"id":"T115","span":{"begin":1083,"end":1210},"obj":"Sentence"},{"id":"T116","span":{"begin":1211,"end":1402},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

LitCovid-PMC-OGER-BB

2_test

{"project":"2_test","denotations":[{"id":"32572532-27365388-47963434","span":{"begin":130,"end":132},"obj":"27365388"},{"id":"32572532-29544767-47963435","span":{"begin":134,"end":136},"obj":"29544767"},{"id":"32572532-29544767-47963436","span":{"begin":373,"end":375},"obj":"29544767"},{"id":"32572532-26282594-47963437","span":{"begin":377,"end":379},"obj":"26282594"},{"id":"32572532-19361301-47963438","span":{"begin":695,"end":697},"obj":"19361301"},{"id":"32572532-22610925-47963439","span":{"begin":1000,"end":1002},"obj":"22610925"},{"id":"32572532-18171251-47963439","span":{"begin":1000,"end":1002},"obj":"18171251"},{"id":"32572532-21768513-47963439","span":{"begin":1000,"end":1002},"obj":"21768513"},{"id":"32572532-22751544-47963439","span":{"begin":1000,"end":1002},"obj":"22751544"},{"id":"32572532-24550381-47963440","span":{"begin":1206,"end":1208},"obj":"24550381"},{"id":"32572532-29544767-47963441","span":{"begin":1398,"end":1400},"obj":"29544767"},{"id":"T59357","span":{"begin":130,"end":132},"obj":"27365388"},{"id":"T21297","span":{"begin":134,"end":136},"obj":"29544767"},{"id":"T78250","span":{"begin":373,"end":375},"obj":"29544767"},{"id":"T9616","span":{"begin":377,"end":379},"obj":"26282594"},{"id":"T50130","span":{"begin":695,"end":697},"obj":"19361301"},{"id":"T88155","span":{"begin":1000,"end":1002},"obj":"22610925"},{"id":"T71393","span":{"begin":1000,"end":1002},"obj":"18171251"},{"id":"T75852","span":{"begin":1000,"end":1002},"obj":"21768513"},{"id":"T42515","span":{"begin":1000,"end":1002},"obj":"22751544"},{"id":"T71499","span":{"begin":1206,"end":1208},"obj":"24550381"},{"id":"T51946","span":{"begin":1398,"end":1400},"obj":"29544767"}],"text":"Treatment options and challenges for IAPA in the ICU\nFirst-line treatment options for IPA include voriconazole and isavuconazole [35, 43]. Other options include echinocandins in combination with anti-mold azoles, and liposomal amphotericin B (L-AmB) in regions with high rates of azole-resistant A. fumigatus, although clinical data with L-AmB in ICU patients are limited [43, 44]. Achieving adequate drug exposure is challenging in ICU patients with multiple factors contributing to pharmacokinetic variability. Unlike L-AmB and the echinocandins, drug interactions are clinically relevant for the azoles and pharmacogenetic factors are important in inter-individual drug exposure variability [45]. The impact of therapeutic drug monitoring (TDM) for voriconazole shows a clear relation between exposure and both efficacy and toxicity. Target plasma trough voriconazole concentrations of ≥ 1.5–2 mg/L are associated with near-maximal clinical response in treatment of IA with a wild-type phenotype [46–51], with higher exposures (\u003e 5.5 mg/L) increasing the risk of (neuro)toxicity. Higher trough concentrations (\u003e 2 mg/L) are recommended for treatment of pathogens with elevated MICs (e.g., \u003e 0.25 mg/L) [52]. For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

PMC:7306567 / 16239-17641 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7306567 / 16239-17641 JSON TXT